cgoncology_cover.jpg
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Transparency Market Research
Bladder Cancer Therapeutics Market is Likely to Reach USD 456.3 million by 2034 at a CAGR of 4.8% | Report Analysis by Transparency Market Research Inc.
August 09, 2024 10:18 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 09, 2024 (GLOBE NEWSWIRE) -- The global bladder cancer therapeutics market(방광암 치료제 시장) stood at US$ 271.4 million in...
cgoncology_cover.jpg
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024 08:23 ET | CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024 08:00 ET | CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
cgoncology_cover.jpg
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024 12:14 ET | CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
cgoncology_cover.jpg
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Logo.png
Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
May 14, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, May 14, 2024 (GLOBE NEWSWIRE) -- Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain ...
cgoncology_cover.jpg
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024 08:00 ET | CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET | CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
biodexa-logo-square (1).png
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024 08:30 ET | Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...